Price T Rowe Associates Inc. MD Invests $197,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)

Price T Rowe Associates Inc. MD acquired a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,242 shares of the biotechnology company’s stock, valued at approximately $197,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Summit Investment Advisors Inc. boosted its position in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares during the period. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $78,000. New York State Common Retirement Fund boosted its position in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 5,000 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $91,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Price Performance

CAPR opened at $9.44 on Friday. The business has a 50 day simple moving average of $10.70 and a 200-day simple moving average of $13.77. The stock has a market capitalization of $431.19 million, a P/E ratio of -8.91 and a beta of 0.85. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same period in the prior year, the firm posted ($0.31) earnings per share. Research analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on CAPR shares. HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Capricor Therapeutics has an average rating of “Buy” and an average target price of $36.40.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.